State-of-the-Art Clinical Symposium

About the ACR
Find A Member
Join
Login

Patient Resources Find a Member

SAVE THE DATE!

April 26 – 27, 2014 • Chicago, Illinois • Sheraton Chicago Hotel & Towers

This clinical symposium exposes attendees to a range of content delivered by key opinion leaders in areas such as therapeutic developments, recent research findings, and scientific advances, all delivered in an environment conducive to dialogue and networking.

Hotel & Travel
Things to See & Do
Syllabus
Recordings
Exhibitors
Supporters
Policies & Disclosures

Past Program Information & Schedule

Overall Learning Objectives
Upon completion of this program, participants should be able to:

discuss the most up-to-date evidence-based treatment approaches in the management of rheumatic diseases
discuss the most recent scientific and clinical advances regarding pathogenesis of rheumatic diseases

Target Audience
This course is designed for rheumatologists, physicians and other healthcare providers who care for patients with rheumatic diseases.

SCHEDULE—SATURDAY, APRIL 20, 2013 Click t1o Expand

SCHEDULE—SATURDAY, APRIL 20, 2013 Click to Hide

7:00 AM CONTINENTAL BREAKFAST

7:30 AM
Update - ABIM Maintenance of Certification Program
Joan M. Von Feldt, MD, MS Ed • University of Pennsylvania; Philadelphia, PA

7:45 AM
Welcome & Introductions
Michael H. Pillinger, MD • New York University Langone Medical Center; New York, NY

8:00 AM
Opening Lecture: Placebo Analgesia in Clinical Trials and Practice
Roland Staud, MD • University of Florida; Gainesville, FL

View Learning ObjectivesClick to Expand

View Learning ObjectivesClick to Hide

At the conclusion of this session participants should be able to:

recognize important factors modulating placebo analgesia
differentiate between classical conditional and expectations as they apply to patient treatment responses
recognize that patient responses to medications are always modulated to some degree by expectation/placebo effects, and adjust clinical practice such that patient treatment responses will be enhanced rather than diminished by placebo effects

8:45 – 10:15 AM
SESSION I: THE BIG THREE

Osteoarthritis: State-of-the-Art and Future Perspectives
Steve B. Abramson, MD • New York University Hospital of Joint Disease; New York, NY

View Learning ObjectivesClick to Expand

View Learning ObjectivesClick to Hide

At the conclusion of this session participants should be able to:

describe the known mechanisms by which osteoarthritis develops and progresses
recognize the role of inflammation in the pathogenesis of osteoarthritis
identify potential biochemical markers that may predict disease progression and how they might facilitate future DMOAD development

New Therapies for Rheumatoid Arthritis
Clifton O. Bingham III, MD • Johns Hopkins University; Baltimore, MD

View Learning ObjectivesClick to Expand

View Learning ObjectivesClick to Hide

At the conclusion of this session participants should be able to:

appropriately utilize the most recently-approved biologic and small molecule therapies for rheumatoid arthritis
describe the mechanisms of action and efficacy data of pipeline biologic and small molecule therapies for rheumatoid arthritis
evaluate future potential agents for rheumatoid arthritis treatment based on the evolving biology of rheumatoid arthritis

Year in Review: Lupus
Elena M. Massarotti, MD • Brigham and Women's Hospital; Boston, MA

View Learning ObjectivesClick to Expand

View Learning ObjectivesClick to Hide

At the conclusion of this session participants should be able to:

review clinical advances in lupus in 2012
discuss drugs in development in 2012-2013
identify current gaps in diagnosis and treatment

10:15 AM BREAK

10:45 – 12:15 PM
SESSION II: PAIN

Mechanisms of Musculoskeletal Pain
Roland Staud, MD • University of Florida; Gainesville, FL

View Learning ObjectivesClick to Expand

View Learning ObjectivesClick to Hide

At the conclusion of this session participants should be able to:

recognize the important role of inflammation for pain
distinguish between peripheral and central pain processing in diagnosis and clinical practice
recognize factors that modulate chronic pain, and modulate these factors to reduce the likelihood and/or impact of chronic pain in patients with rheumatic diseases

Update on Treatment Options for Low Back Pain
David G. Borenstein, MD • Arthritis & Rheumatism Association; Washington, DC

View Learning ObjectivesClick to Expand

View Learning ObjectivesClick to Hide

At the conclusion of this session participants should be able to:

review the common underlying etiologies of low back pain by diagnostic category
interpret the literature on efficacy of epidural injections
discuss data on efficacy of artificial discs
compare non-pharmacologic therapies for low back pain

Pediatric Amplified Pain: When it Is and When it Isn't
David D. Sherry, MD • Children's Hospital of Philadelphia; Philadelphia, PA

View Learning ObjectivesClick to Expand

View Learning ObjectivesClick to Hide

At the conclusion of this session participants should be able to:

explain the diagnosis of amplified pain in children
list differential diagnostic entities in considering pediatric amplified pain
discuss treatment options for amplified pain in children
recognize and diagnose conversion

12:15 PM BOXED LUNCH

12:30 – 1:30 PM
LUNCH SESSIONS (Space is limited. Separate registration fees apply unless indicated otherwise.)

A Look at the ACR 2012 Guidelines for Gout Management: Consensus (and just a little controversy!)
Michael H. Pillinger, MD • New York University Langone Medical Center; New York, NY

Pediatric Rheumatology for the Adult Rheumatologist
David D. Sherry, MD • Children's Hospital of Philadelphia; Philadelphia, PA

View Learning ObjectivesClick to Expand

View Learning ObjectivesClick to Hide

At the conclusion of this session participants should be able to:

understand key aspects and pearls of pediatric rheumatology that adult rheumatologists should know

Rehabilitation
Kenneth S. O'Rourke, MD • Wake Forest School of Medicine; Winston-Salem, NC

View Learning ObjectivesClick to Expand

View Learning ObjectivesClick to Hide

At the conclusion of this session participants should be able to:

discuss available rehabilitative strategies, and their evidence base, for the treatment of patients with selected musculoskeletal conditions
incorporate information on rehabilitative strategies into the formation of a therapy prescription

ANCA-Associated Vasculitis
John H. Stone, MD, MPH • Harvard Medical School; Cambridge, MA

View Learning ObjectivesClick to Expand

View Learning ObjectivesClick to Hide

At the conclusion of this session participants should be able to:

understand current approaches to the induction of remission in ANCA-associated vasculitis
gain insight into the impact of both rituximab and cyclophosphamide on B cell kinetics and to appreciate the implications of this for therapy
recognize complications of therapies and appreciate means by which these may be avoided

Disease Assessment in Rheumatoid Arthritis
Joan M. Bathon, MD • Columbia University Medical Center; New York, NY

View Learning ObjectivesClick to Expand

View Learning ObjectivesClick to Hide

At the conclusion of this session participants should be able to:

recognize the importance of disease activity assessment in the management of a patient with rheumatoid arthritis
distinguish the utility of disease activity assessment in a treat to target approach
distinguish between different tools used in disease activity assessment in patients with rheumatoid arthritis

Pharmacotherapy for the Treatment of Non-renal Lupus
Elena M. Massarotti, MD • Brigham and Women's Hospital; Boston, MA

View Learning ObjectivesClick to Expand

View Learning ObjectivesClick to Hide

At the conclusion of this session participants should be able to:

list the mechanisms of action, toxicities, and dosing of the immunosuppressive medications used to treat non-renal lupus
identity treatment strategies for specific manifestations of non-renal lupus
review the evidence based literature that inform these treatment decisions

Practical Approach to Common Low Back Pain Syndromes through Case Vignettes
David G. Borenstein, MD • Arthritis & Rheumatism Association; Washington, DC

View Learning ObjectivesClick to Expand

View Learning ObjectivesClick to Hide

At the conclusion of this session participants should be able to:

review typical clinical presentations of common low back pain syndromes including spinal stenosis, disc herniation, osteoarthritis and muscle strain
discuss management of these syndromes through case examples

Risk Evaluation and Mitigation Strategies (NO FEE)
Allan Gibofsky, MD, JD • Hospital for Special Surgery; New York, NY

View Learning ObjectivesClick to Expand

View Learning ObjectivesClick to Hide

At the conclusion of this session participants should be able to:

explain the magnitude of use of extended release and long acting opioids
identify the elements of a risk evaluation mitigation program (REMS)
discuss the FDA REMS on extended release and long acting opioids

From Spondylarthropathy to Spondylarthritis: Diagnosis, Classification, Treatment (NO FEE)
Marcello Govoni, MD • University of Ferrara; Ferrara, Italy
Ignazio Olivieri, MD • San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera; Potenza, Italy

View Learning ObjectivesClick to Expand

View Learning ObjectivesClick to Hide

At the conclusion of this session participants should be able to:

apply the new ASAS classification to categorize patients with various types of spondylarthritis
recognize the challenges of diagnosing undifferentiated spondylarthritis
apply the latest knowledge to optimize the management of spondylarthritides, particularly the use of biologic agents
distinguish the biology and management of spondylarthritis from those of rheumatoid arthritis

1:45 – 3:15 PM
SESSION III: MUSCLE DISEASE

Myositis
Paul H. Plotz, MD • NIAMS NIH; Bethesda, MD

View Learning ObjectivesClick to Expand

View Learning ObjectivesClick to Hide

At the conclusion of this session participants should be able to:

discuss the differential diagnosis of a patient presenting with muscle weakness and elevation of the CPK
review diagnostic pearls to avoid incorrect diagnosis of myositis
analyze treatment options in newly diagnosed and refractory myositis and dermatomyositis

Metabolic Myopathies
Kenneth S. O'Rourke, MD • Wake Forest School of Medicine; Winston-Salem, NC

View Learning ObjectivesClick to Expand

View Learning ObjectivesClick to Hide

At the conclusion of this session participants should be able to:

discuss the sources of energy for muscle metabolism
describe the evaluation of a patient presenting with a suspected metabolic myopathy, correlating defects in energy production pathways with symptoms
summarize available therapies for patients with metabolic myopathies

Fellow Case Presentations with Speaker Panel
Kenneth S. O'Rourke, MD • Wake Forest School of Medicine; Winston-Salem, NC
Paul H. Plotz, MD • NIAMS NIH; Bethesda, MD

3:15 PM BREAK

3:30 – 5:00 PM
SESSION IV: HOT TOPICS

IgG4-Related Disease
John H. Stone, MD, MPH • Harvard Medical School; Cambridge, MA

View Learning ObjectivesClick to Expand

View Learning ObjectivesClick to Hide

At the conclusion of this session participants should be able to:

appreciate the breadth of organ system manifestations of IgG4-related disease
recognize the ways in which this new rheumatologic condition mimics established rheumatologic conditions
gain insight into current treatment approaches for IgG4-related disease and to appreciate what mechanistic studies on this condition can tell us about the immune system

Vaccinations in Patients with Rheumatic Diseases
Clifton O. Bingham III, MD • Johns Hopkins University; Baltimore, MD

View Learning ObjectivesClick to Expand

View Learning ObjectivesClick to Hide

At the conclusion of this session participants should be able to:

recognize the impact that rheumatic diseases have on the efficacy of various vaccines, and the importance of vaccination in these same patients
describe the potential risks of recombinant versus live attenuated vaccines as these apply to specific rheumatic diseases, disease activities and immunosuppressive therapies
develop a treatment algorithm for vaccination of rheumatic disease patients, in order to promote optimal vaccine efficacy with minimally possible adverse effects

Cardiovascular Disease in Rheumatoid Arthritis
Joan M. Bathon, MD • Columbia University Medical Center; New York, NY

View Learning ObjectivesClick to Expand

View Learning ObjectivesClick to Hide

At the conclusion of this session participants should be able to:

elucidate the difference in prevalence/incidence of cardiovascular disease and cardiovascular risk factors in rheumatoid arthritis versus matched controls
delineate the effect of rheumatoid arthritis and inflammation on cardiovascular metabolic pathways
probe the effect of rheumatoid arthritis treatment on risk of cardiovascular disease in rheumatoid arthritis patients

SCHEDULE—SUNDAY, APRIL 21, 2013 Click to Expand

SCHEDULE—SUNDAY, APRIL 21, 2013 Click to Hide

7:00 AM CONTINENTAL BREAKFAST

7:00 – 8:00 AM
BREAKFAST SESSIONS (Space is limited. Separate registration fees apply unless indicated otherwise.)

Interpreting Efficacy Data from Rheumatoid Arthritis RCTs: How should we implement what we learn in routine clinical care?
Yusuf Yazici, MD • New York University Hospital for Joint Diseases; New York, NY

View Learning ObjectivesClick to Expand

View Learning ObjectivesClick to Hide

At the conclusion of this session participants should be able to:

define a treatment target and implement treat-to-target strategies in rheumatoid arthritis management
know how to use and score the various composite indices to assess rheumatoid arthritis disease activity, and be able to identify the optimal outcome measure(s) to apply to specific individual practice settings
distinguish between clinically relevant versus merely statistically important changes in the various rheumatoid arthritis disease scales

Pathology: Lupus Nephritis
Anthony Chang, MD • University of Chicago; Chicago, IL

View Learning ObjectivesClick to Expand

View Learning ObjectivesClick to Hide

At the conclusion of this session participants should be able to:

understand the pathologic findings and classification of lupus nephritis

State of the Union: An Update in the Politics and Business of Rheumatology (NO FEE)
Timothy Laing, MD • University of Michigan Medical Center; Ann Arbor, MI

View Learning ObjectivesClick to Expand

View Learning ObjectivesClick to Hide

At the conclusion of this session participants should be able to:

summarize political updates in healthcare and understand the impact on the practice of rheumatology
understand the best ways to engage in political advocacy

The Connected Rheumatology Practice: EHR Implementation and Customization (NO FEE)
Salahuddin Kazi, MD • UT Southwestern Medical Center; Dallas, TX
William McClatchey, MD • Piedmont Healthcare; Atlanta, GA

View Learning ObjectivesClick to Expand

View Learning ObjectivesClick to Hide

At the conclusion of this session participants should be able to:

discuss the key elements in current clinical processes and workflow to help select the features of an EHR that will be most useful for a rheumatology clinical practice
identify common obstacles in EHR implementation and identify strategies to mitigate those barriers
employ strategies to work effectively with an EHR vendor to incorporate rheumatology-specific templates into the EHR system

8:15 – 9:45 AM
SESSION V: OSTEOPOROSIS

Controversy of Treatment: Calcium & Vitamin D
Clifford Rosen, MD • Maine Medical Research Institute; Scarborough, ME

View Learning ObjectivesClick to Expand

View Learning ObjectivesClick to Hide

At the conclusion of this session participants should be able to:

discuss normal metabolism and handling of Vitamin D
understand the literature behind the recommendations for calcium and Vitamin D supplementation
review the current data and controversies regarding recommendations for calcium and Vitamin D intake
counsel patients on calcium and Vitamin D supplementation for various clinical scenarios including, normal aging, osteoporosis, and diseases requiring steroid therapy

Bisphosphonate Therapy
Michael McClung, MD • Oregon Osteoporosis Center; Portland, OR

View Learning ObjectivesClick to Expand

View Learning ObjectivesClick to Hide

At the conclusion of this session participants should be able to:

recognize the clinical picture and epidemiology of typical fractures associated with bisphosphonate therapy
appreciate the benefit-risk relationship with long-term bisphosphonate therapy
review the recent FDA recommendations regarding duration of bisphosphonate use

Audience Discussion with Speaker Panel
Michael McClung, MD • Oregon Osteoporosis Center; Portland, OR
Clifford Rosen, MD • Maine Medical Research Institute; Scarborough, ME

9:45 AM BREAK

10:15 – 11:45 AM
SESSION VI: VASCULITIS

Behcet's Syndrome: What It Is, and What It Is Not
Yusuf Yazici, MD • New York University Hospital for Joint Diseases; New York, NY

View Learning ObjectivesClick to Expand

View Learning ObjectivesClick to Hide

At the conclusion of this session participants should be able to:

identify patients with possible Behcet's syndrome, develop a working differential diagnosis, and make the diagnosis where appropriate
know the immunosuppressive approaches most useful in Behcet's syndrome, and initiate treatment in appropriate patients
incorporate knowledge of the natural history of Behcet's, as well as the role of gender and ethnic/racial background in risk stratification and treatment of the Behcet's patient

Viral Infectious Arthritis
Leonard Calabrese, DO • Cleveland Clinic Foundation; Cleveland, OH

View Learning ObjectivesClick to Expand

View Learning ObjectivesClick to Hide

At the conclusion of this session participants should be able to:

understand the microbiology and natural history and epidemiology of viral hepatitis (B and C)
comprehend how to order and interpret serologies to detect chronic, persistent, and recovered infection

Central Nervous System Vasculitis
Leonard Calabrese, DO • Cleveland Clinic Foundation; Cleveland, OH

View Learning ObjectivesClick to Expand

View Learning ObjectivesClick to Hide

At the conclusion of this session participants should be able to:

recognize the clinical and neuroradiographic symptoms of PACNS
execute the diagnosis and algorithm for management of PACNS
recognize and differentiate disease mimics

ADDITIONAL ACTIVITIES Click to Expand

ADDITIONAL ACTIVITIES Click to Hide

The following activities are offered in conjunction with, or concurrent to, the 2013 State-of-the-Art Clinical Symposium (separate/additional fees may apply):

Friday, April 19

Clinical Rheumatology for Health Professionals: ABCs of X-ray Reading
Fellows-in-Training Program. Contact fittravel@rheumatology.org for more information.

Saturday, April 20

Musculoskeletal Ultrasound for Rheumatologists Course—Fundamentals (Day One)

Sunday, April 21

Musculoskeletal Ultrasound for Rheumatologists Course—Fundamentals (Day Two)

REGISTRATION & FEESClick to Expand

REGISTRATION & FEESClick to Hide

The registration fees are available until 12:00 midnight EST on the dates listed.

Registration Confirmations
Attendees who pre-register by April 3, should receive a confirmation within seven business days. If you do not receive your confirmation, please call (800) 636-4766 (US & Canada) or (415) 979-2265 (international) or send notice via email to ACRProfMtgs@cmrus.com.

Registration Cancellations
Cancellations must be received in writing by April 1. No refunds will be issued after this date.

All cancellations or refund requests received before 14 business days from the meeting will incur a $50 administrative fee.
All cancellations or refund requests received within 14 business days leading into the meeting will not receive a refund.

All refund requests will be processes after the event. No refunds will be issued onsite at the event. Cancelled registrations are non-transferable. Send requests via email to ACRProfMtgs@cmrus.com or fax to (415) 216-2537.

Press Registration
For a press registration form, contact Erin Latimer at ELatimer@rheumatology.org or (404) 633-3777. All press registrations must be confirmed 10 days in advance of the meeting and will not be issued on-site.

Press passes are issued to individuals representing a recognized news organization, including freelancers who contribute to such organizations. To obtain a press badge, both photo identification, such as a driver's license or passport, and identification certifying that you are a working member of the print, broadcast or online media are required. Such identification includes press credentials, or a business card and samples of your work. All freelancers must present a letter of assignment. Individuals who receive exhibitor passes are not eligible for press passes. The ACR has the right to inspect the credentials of anyone registering and reserves the right to refuse to register any individual as press.

Ineligible Registrants: The ACR does not issue press badges to: publishers or a publications' advertising, marketing, public relations, sales, circulation, or any other non-editorial function representatives; industry/exhibitor press officers and their public relations consultants; financial or business analysts; educational program developers (including CME writers and editors, and those writers and editors working on behalf of organizations that have written CME based on ACR meeting content); trade media management personnel; or other individuals who are not actually reporting on the meeting.

Media who produce a communications vehicle that is sponsored by a single organization or whose revenue for the publication or issue of a publication depends solely on coverage of the ACR's meeting also are ineligible to receive press credentials. In addition, media who produce communications vehicle that uses the ACR's name or logo to imply endorsement from the ACR also are ineligible to receive press credentials. The ACR prohibits the development of CME content based on information presented at its meeting.

Be advised that based on space requirements, the ACR reserves the right to limit the number of press badges issued to a media organization. Typically, no more than two press passes will be issued to any one news organization.

2013 State-of-the-Art Clinical Symposium
REGISTRATION CATEGORIES	EARLY BIRD REGISTRATION FEE by March 6, 2013	ADVANCE REGISTRATION FEE by April 3, 2013	ONSITE REGISTRATION FEE after April 3, 2013
ACR/ARHP MEMBER	$335.00	$430.00	$495.00
NON-MEMBER	$500.00	$640.00	$735.00
FIT MEMBER	$170.00	$345.00	$400.00
NON-MEMBER FIT	$270.00	$510.00	$590.00
RESIDENT/STUDENT MEMBER	$170.00	$345.00	$400.00
RESIDENT/STUDENT NON-MEMBER	$240.00	$485.00	$565.00
MASTER/EMERITUS	$170.00	$345.00	$400.00
LUNCH SESSIONS	$30.00	$30.00	$30.00

HOTEL & TRAVELClick to Expand

HOTEL & TRAVELClick to Hide

Hotel Accommodations
To make housing reservations, contact the hotel directly and identify yourself as an attendee of the ACR State-of-the-Art Clinical Symposium. ACR reduced rates are subject to room availability through Friday, March 22, 2013. After this date, room rates cannot be guaranteed. Check with the hotel for any early departure fees and cancellation/refund policies.

Sheraton Chicago Hotel & Towers
301 East North Water Street
Chicago, IL 60611
Phone: (800) 325-3535 or (312) 464-1000
Fax: (312) 464-9140
Website: www.sheratonchicago.com

Rates: $249 single/double per night (standard rooms)
$299 single/double per night (club level rooms)
$20 charge per additional person
No charge for children under 18 years of age staying with parents

Tax: Room rates are subject to city/state taxes. The current rate is 16.4% (tax rate is subject to change).

Direct Dial Reservations: Call the hotel directly at (800) 325-3535.
Website: https://www.starwoodmeeting.com/Book/ACR2013

Airline Reservations
To make your airline or car rental reservations, contact ACR's travel agency. Be sure to book early to obtain the best travel options.

Association Travel Concepts:
(800) 755-3899 or (858) 362-2719
Email: reservations@atcmeetings.com
Website: www.atcmeetings.com/ACR

Ground Transportation
Rates listed are subject to change.

O'Hare International Airport:
(18 miles/30-60 minutes to Sheraton Chicago Hotel & Towers)
Airport Express Shuttle is $25 one-way; $46 round-trip
Taxi fare is approximately $35 - $45.
www.ohare.com

Midway Airport:
(10 miles/20-40 minutes to Sheraton Chicago Hotel & Towers)
Airport Express Shuttle is $20 one-way; $36 round-trip
Taxi fare is approximately $25 -$30.
www.ifly.com/chicago-midway-international-airport

Continental Go Airport Express Shuttle:
Phone: (800) 654-7871
Website: www.airportexpress.com

For additional information and train travel visit www.transitchicago.com or contact the hotel concierge. Hotel parking: Valet nightly parking is $51 with in-out privileges; self-parking is $39 per 24 hour period.

THINGS TO SEE & DOClick to Expand

THINGS TO SEE & DOClick to Hide

Chicago Convention and Tourism Bureau
2301 South Lake Shore Drive
Chicago, IL 60616
Phone: (312) 567-8500
Website: www.choosechicago.com

The Sheraton Chicago Hotel & Towers is located in the heart of downtown Chicago. Overlooking the Chicago River, the hotel is within walking distance of Navy Pier, Magnificent Mile, Millennium Park, the Loop business district, Art Institute and more.

SYLLABUSClick to Expand

SYLLABUSClick to Hide

To ensure attendees have the most updated copy of each speaker's presentation, syllabi will be available online following the 2013 symposium for registered attendees.

Access the syllabus from the 2012 State-of-the-Art Clinical Symposium (requires password distributed to registered 2012 registered attendees).

RECORDINGSClick to Expand

RECORDINGSClick to Hide

If you are interested in revisiting, or viewing for the first time, the content that was covered at past State-of-the-Art Clinical Symposia meetings, you can order recordings of the live sessions through SessionSelect.

Order now and gain instant access to presentations from this year's State-of-the-Art Clinical Symposium!

If you have questions about SessionSelect or other ACR/ARHP educational resources, e-mail products@rheumatology.org.

Note: CME credits are not available for viewing the recorded course.
System Requirements: To access SessionSelect, it is recommended you use Internet Explorer, Firefox or Safari. If you are prompted to download Microsoft Silverlight, follow the prompts and download the program to access the streaming videos.

EXHIBITORSClick to Expand

EXHIBITORSClick to Hide

2013 State-of-the-Art Clinical Symposium Tabletop Display Exhibitors

4S Dawn Clinical Software
AbbVie
Alpinion Medical Systems
Amgen
Bristol-Myers Squibb
Constant Media
ContextMedia Health
Crescendo Bioscience
Esaote North America, Inc.
GE Healthcare
Genentech

GlaxoSmithKline
Horizon Pharma, Inc.
Janssen Biotech
Novartis Pharmaceuticals
PatientPoint
Pfizer
Questcor
Savient
Takeda
TheraTest Labs
UCB